US2002173457A1PendingUtilityA1

LicD1

55
Priority: Feb 28, 1997Filed: Mar 29, 2001Published: Nov 21, 2002
Est. expiryFeb 28, 2017(expired)· nominal 20-yr term from priority
Inventors:Michael Arthur Lonetto
C07K 2319/00C07K 14/3156A61P 31/04A61K 38/00A61P 37/04A61K 39/00
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides licD1 polypeptides and polynucleotides encoding licD1 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing licD1 polypeptides to screen for antibacterial compounds.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . An isolated polypeptide comprising a fragment of SEQ ID NO:2 comprising at least 50 consecutive amino acids of SEQ ID NO:2; wherein said fragment has licD1 activity.  
     
     
         2 . A composition comprising the isolated polypeptide of  claim 1  and a carrier.  
     
     
         3 . The isolated polypeptide of  claim 1 , wherein the isolated polypeptide comprises a heterologous amino acid sequence fused to the at least 50 consecutive amino acids of SEQ ID NO:2.  
     
     
         4 . A composition comprising the isolated polypeptide of  claim 3  and a carrier.  
     
     
         5 . An isolated polypeptide comprising a fragment of SEQ ID NO:2 comprising at least 30 consecutive amino acids of SEQ ID NO:2; wherein said fragment has licD1 activity.  
     
     
         6 . A composition comprising the isolated polypeptide of  claim 5  and a carrier.  
     
     
         7 . The isolated polypeptide of  claim 5 , wherein the isolated polypeptide comprises a heterologous amino acid sequence fused to the at least 30 consecutive amino acids of SEQ ID NO:2.  
     
     
         8 . A composition comprising the isolated polypeptide of  claim 7  and a carrier.  
     
     
         9 . An isolated polypeptide comprising a fragment of SEQ ID NO:2 comprising at least 50 consecutive amino acids of SEQ ID NO:2; wherein said fragment has the ability to generate antibodies to SEQ ID NO:2.  
     
     
         10 . A composition comprising the isolated polypeptide of  claim 9  and a carrier.  
     
     
         11 . The isolated polypeptide of  claim 9 , wherein the isolated polypeptide comprises a heterologous amino acid sequence fused to the at least 50 consecutive amino acids of SEQ ID NO:2.  
     
     
         12 . A composition comprising the isolated polypeptide of  claim 11  and a carrier.  
     
     
         13 . An isolated polypeptide comprising a fragment of SEQ ED NO:2 comprising at least 30 consecutive amino acids of SEQ ID NO:2; wherein said fragment has the ability to generate antibodies to SEQ ID NO:2.  
     
     
         14 . A composition comprising the isolated polypeptide of  claim 13  and a carrier.  
     
     
         15 . The isolated polypeptide of  claim 13 , wherein the isolated polypeptide comprises a heterologous amino acid sequence fused to the at least 30 consecutive amino acids of SEQ ID NO:2.  
     
     
         16 . A composition comprising the isolated polypeptide of  claim 15  and a carrier.

Join the waitlist — get patent alerts

Track US2002173457A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.